Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5918 | PPDA |
| Subtype-selective NMDA receptor antagonist that preferentially binds to NR2C/NR2D-containing receptors (Ki values are 0.096, 0.125, 0.31 and 0.55 μM for NR2C, NR2D, NR2B and NR2A subunits respectively). | |
| BCC5924 | CFM 1571 hydrochloride |
| Soluble guanylyl cyclase (sGC) activator (EC50 = 5.49 μM). Does not activate adenylyl cyclase, shows no significant inhibition of phosphodiesterases and displays minimal inhibition of iNOS (25%) and nNOS (17%). Inhibits collagen-stimulated platelet aggregation in vitro (IC50 = 2.84 μM). | |
| BCC5925 | DOI hydrochloride |
| Brain penetrant, mixed 5-HT2A/5-HT2C receptor agonist (Ki values are 0.7, 2.4 and 20 nM for 5-HT2A, 5-HT2C and 5-HT2B receptors respectively). Reduces rapid eye movement (REM) and slow wave sleep and increases waking in the rat. Hallucinogenic agent. Acts via 5-HT2A receptors to inhibit the inflammatory effects of tumor necrosis factor (TNF)-α. | |
| BCC5938 | KF 38789 |
| Selective inhibitor of P-selectin-mediated cell adhesion (IC50 = 1.97 μM) that displays no effects on L-selectin- and E-selectin-mediated adhesion. Blocks P-selectin-mediated binding in vitro and leukocyte accumulation in vivo. | |
| BCC5946 | HU 211 |
| NMDA antagonist (IC50 = 11 μM for inhibition of [3H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC50 = 3.8 μM) and enhances dopamine D1 receptor activity. Inhibits NF-κB, reducing TNF-α, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant. | |
| BCC5948 | SC 58125 |
| Selective cyclooxygenase 2 (COX-2) inhibitor (IC50 values are 0.04 and >100 μM for COX-2 and COX-1 respectively). Anti-inflammatory; blocks edema and hyperalgesia in vivo following an inflammatory insult, without causing gastric mucosal damage. Also displays antitumor activity. | |
| BCC5952 | SNX 482 |
| Potent and selective, voltage-dependent R-type CaV2.3 calcium channel blocker (IC50 = 30 nM). Antinociceptive; inhibits nociceptive C-fibre and Aδ-fibre-evoked neuronal responses. | |
| BCC5954 | Diprenorphine |
| Non-selective opioid receptor antagonist (Ki values are 0.017, 0.072 and 0.23 nM for κ-, μ- and δ-opioid receptors). | |
